-+ 0.00%
-+ 0.00%
-+ 0.00%

Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma

PUBT·06/03/2026 20:08:30
Listen to the news
Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma
  • Australia’s TGA granted conditional approval for Iovance’s Amtagvi (lifileucel) in previously treated unresectable or metastatic melanoma.
  • Clearance covers adults who received prior PD-1 therapy; BRAF V600-positive patients must also have had BRAF-targeted treatment.
  • Decision relied on Phase 2 C-144-01 data, supporting the company’s expansion into additional high-melanoma markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606031605PRIMZONEFULLFEED9731483) on June 03, 2026, and is solely responsible for the information contained therein.